Literature DB >> 2060599

The dopamine D1 receptor is involved in the regulation of REM sleep in the rat.

M Trampus1, N Ferri, A Monopoli, E Ongini.   

Abstract

The dopamine D1 receptor agonist, SKF 38393, and the D1 antagonist, SCH 23390, were studied for their effects on sleep in the rat. Over 6 h, SKF 38393 (0.1-10 mg/kg s.c.) dose dependently reduced the amount of rapid eye movement (REM) sleep and enhanced the duration of wakefulness. The drug affected REM at low doses (ED50 = 0.4 mg/kg) at which wakefulness was unchanged and the characteristic grooming behavior was not apparent. REM changes were characterized by a decrease in the number of episodes with no alteration of latency to the first episode. Over a very low dose range (0.003-0.3 mg/kg s.c.), SCH 23390 enhanced the amount of REM by increasing both number and average duration of episodes. There was also a moderate increase of non-REM sleep but the percent change was less marked than that occurring for REM. Given at 0.003 mg/kg, SCH 23390 prevented the REM changes induced by SKF 38393 (0.3-3 mg/kg). It is suggested that D1 receptors are involved in the regulation of the REM sleep process.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060599     DOI: 10.1016/0014-2999(91)90104-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

Review 1.  Neurobiological mechanisms for the regulation of mammalian sleep-wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence.

Authors:  Subimal Datta; Robert Ross Maclean
Journal:  Neurosci Biobehav Rev       Date:  2007-03-12       Impact factor: 8.989

Review 2.  Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective.

Authors:  Antonio Alcaro; Robert Huber; Jaak Panksepp
Journal:  Brain Res Rev       Date:  2007-08-21

Review 3.  Sleep disorders in patients with Parkinson's disease: epidemiology and management.

Authors:  J P Larsen; E Tandberg
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Dopamine D1 Receptor in the Nucleus Accumbens Modulates the Emergence from Propofol Anesthesia in Rat.

Authors:  Yi Zhang; Huan Gui; Zikun Duan; Tian Yu; Jie Zhang; Xiaoli Liang; Chengxi Liu
Journal:  Neurochem Res       Date:  2021-03-08       Impact factor: 3.996

5.  Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Cathy Wood-Siverio; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

6.  Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice.

Authors:  E Tirelli; P Terry
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Sleep and Wakefulness Are Controlled by Ventral Medial Midbrain/Pons GABAergic Neurons in Mice.

Authors:  Yohko Takata; Yo Oishi; Xu-Zhao Zhou; Emi Hasegawa; Koji Takahashi; Yoan Cherasse; Takeshi Sakurai; Michael Lazarus
Journal:  J Neurosci       Date:  2018-10-03       Impact factor: 6.167

8.  Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits.

Authors:  E Ongini; P Bo; S Dionisotti; M Trampus; F Savoldi
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Amphetamine acts within the lateral hypothalamic area to elicit affectively neutral arousal and reinstate drug-seeking.

Authors:  Brooke E Schmeichel; Craig W Berridge
Journal:  Int J Neuropsychopharmacol       Date:  2013-07-29       Impact factor: 5.176

10.  Neurotoxic N-methyl-D-aspartate lesion of the ventral midbrain and mesopontine junction alters sleep-wake organization.

Authors:  Y Y Lai; T Shalita; T Hajnik; J P Wu; J S Kuo; L G Chia; J M Siegel
Journal:  Neuroscience       Date:  1999-05       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.